MEDICINAL-PLANTS IN TROPICAL MEDICINE .2. NATURAL-PRODUCTS IN CANCER-TREATMENT FROM BENCH TO THE CLINIC

被引:12
作者
FOX, BW
机构
[1] Operational Secretary, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, M20 9BX, Wilmslow Road
关键词
D O I
10.1016/0035-9203(91)90140-T
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The development of anticancer agents has, in the past, relied heavily on leads derived from screening a wide variety of agents from both synthetic and natural sources. With the development of new techniques of measurement of biochemical changes in cells and the advent of molecular biological techniques, it is becoming clear that many naturally occurring agents, specifically selected for their tumour growth inhibiting activity, are highly complex and novel substances which are potentially promising as anticancer agents in the clinic. The process of getting a drug from the laboratory bench to the clinic is itself often complex due to adverse physical characteristics of the drug. The experience of the Cancer Research Campaign Clinical Trials Committee in developing several natural products, currently in various stages of development for clinical trial, is described. The drugs discussed include the vinca alkaloids, maytansine, combretastatins, bryostatin 1, pancratistatin, phyllanthoside, dolastatin 10, and taxol.
引用
收藏
页码:22 / 25
页数:4
相关论文
共 13 条
[1]  
COLLINS JM, 1986, CANCER TREAT REP, V70, P73
[2]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
[3]  
GOLDSMITH MA, 1975, CANCER RES, V35, P1354
[4]  
KUPCHAN SM, 1976, CANCER TREAT REP, V60, P1115
[5]   TUMOR INHIBITORS .120. PHYLLANTHOCIN, A NOVEL BISABOLANE AGLYCONE FROM ANTILEUKEMIC GLYCOSIDE, PHYLLANTHOSIDE [J].
KUPCHAN, SM ;
LAVOIE, EJ ;
BRANFMAN, AR ;
FEI, BY ;
BRIGHT, WM ;
BRYAN, RF .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (09) :3199-3201
[6]   DIFFERENTIAL CYTOTOXICITY OF COMBRETASTATIN-A1 AND COMBRETASTATIN-A4 IN 2 DAUNORUBICIN-RESISTANT P388 CELL-LINES [J].
MCGOWN, AT ;
FOX, BW .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (01) :79-81
[7]   ROLE OF CHANCE OBSERVATIONS IN CHEMOTHERAPY - VINCA-ROSEA [J].
NOBLE, RL ;
BEER, CT ;
CUTTS, JH .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1958, 76 (03) :882-894
[8]   ANTINEOPLASTIC AGENTS .136. THE ISOLATION AND STRUCTURE OF A REMARKABLE MARINE ANIMAL ANTINEOPLASTIC CONSTITUENT - DOLASTATIN 10 [J].
PETTIT, GR ;
KAMANO, Y ;
HERALD, CL ;
TUINMAN, AA ;
BOETTNER, FE ;
KIZU, H ;
SCHMIDT, JM ;
BACZYNSKYJ, L ;
TOMER, KB ;
BONTEMS, RJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1987, 109 (22) :6883-6885
[9]   ANTINEOPLASTIC AGENTS .145. ISOLATION AND STRUCTURE OF THE STRONG CELL-GROWTH AND TUBULIN INHIBITOR COMBRETASTATIN-A-4 [J].
PETTIT, GR ;
SINGH, SB ;
HAMEL, E ;
LIN, CM ;
ALBERTS, DS ;
GARCIAKENDALL, D .
EXPERIENTIA, 1989, 45 (02) :209-211
[10]  
ROZENCWEIG M, 1981, CANCER CLIN TRIALS, V4, P21